Sialoendoscopy TMJ Microarthroscopy Breast Endoscopy ... · Salivary Glands –Summary The...

11

SialoendoscopySialoendoscopyTMJ TMJ MicroarthroscopyMicroarthroscopy

Breast Breast EndoscopyEndoscopyLachrymal Lachrymal EndoscopyEndoscopy

Root Canal Root Canal EndoscopyEndoscopy

Innovation in Micro TechnologyInnovation in Micro Technology

Nov 2008Nov 2008

22

Company ProfileCompany Profile

•• Medical device company founded in Oct. 2002Medical device company founded in Oct. 2002•• Public company on TASE (Feb. 2007)Public company on TASE (Feb. 2007) ,SALO .,SALO .•• Complete solution for Salivary Glands .Complete solution for Salivary Glands .•• SialoSialo R&D solutions for patient care. R&D solutions for patient care.

SIALO TECHNOLOGY SPECIALIZES IN MICROENDOSCOPY:SIALO TECHNOLOGY SPECIALIZES IN MICROENDOSCOPY:

1.1. Rigid Rigid -- Wide range of productsWide range of products

2.2. Flexible Flexible :: The "VascoCath" The "VascoCath" –– steerablesteerable catheters for catheters for Interventional Radiology inInterventional Radiology in the Vascular System.the Vascular System.

33

The Management TeamThe Management Team

•• Itzhak HenigItzhak Henig-- CEO, has extensive experience in management in Israel and abroad, responsible for the success of the laser project in the incubator program.

•• Reuven Breslauer Reuven Breslauer -- Marketing Manager,and a pioneer in marketing of endoscope systems in Israel, years of connection and experience with worldwide manufacturers, suppliers, and distributors.

44

Scientific advisersScientific advisers•• Prof. Prof. OdedOded NahlieliNahlieli –– Graduated from the Hebrew University Hadassah School of Graduated from the Hebrew University Hadassah School of

Dental medicine in Jerusalem. He completed his Oral and MaxillofDental medicine in Jerusalem. He completed his Oral and Maxillofacial Surgery residency acial Surgery residency in Israel and in the Oral and Maxillofacial Surgery Department iin Israel and in the Oral and Maxillofacial Surgery Department in Massachusetts General n Massachusetts General Hospital Boston USA. He is the chairman of the Department of OraHospital Boston USA. He is the chairman of the Department of Oral and Maxillofacial l and Maxillofacial Surgery at Surgery at BarzilaiBarzilai Medical Medical CenterCenter AshkelonAshkelon, Israel, an Associate Professor at the Hebrew , Israel, an Associate Professor at the Hebrew University University –– Hadassah School of Dental Medicine and Adjunct Associate ProfesHadassah School of Dental Medicine and Adjunct Associate Professor at the sor at the New York University College of Dentistry. New York University College of Dentistry. Since 1993, Prof. Since 1993, Prof. NahlieliNahlieli began developing the began developing the practice of practice of EndoscopyEndoscopy of the salivary glands and was one of the pioneers in the fieldof the salivary glands and was one of the pioneers in the field..

• Joshua Raif Joshua Raif -- R&D Manager (SialoR&D Manager (Sialo--Lite), Lite), physicistphysicist, renowned worldwide for his , renowned worldwide for his contribution to laser systems and accessories in the medical fiecontribution to laser systems and accessories in the medical fieldld, including lasers for , including lasers for endoscopic applicationendoscopic applicationss..

•• Prof. Joshua Musahanov Prof. Joshua Musahanov -- Acting Head of the Acting Head of the EndodonticEndodontic Department at the Department at the Hadassah School of Dental Medicine Hadassah School of Dental Medicine --SialotechnologySialotechnology EndodonticEndodontic consultant. He is an consultant. He is an international leading expert in root canal treatment and laser rinternational leading expert in root canal treatment and laser research.esearch.

International AdvisorsInternational Advisors

•• Prof. Mark Prof. Mark McGurkMcGurk-- Chairman Department of OMFS GuyChairman Department of OMFS Guy’’s Hospital London GBs Hospital London GB•• Prof. Heinrich Prof. Heinrich IroIro-- Chairman Department of Head and Neck Erlangen Chairman Department of Head and Neck Erlangen ––Nuremburg GermanyNuremburg Germany•• Dr. Philippe KatzDr. Philippe Katz-- NeuroradiologstNeuroradiologst American Hospital Paris FranceAmerican Hospital Paris France•• Prof. Eli Eliav Prof. Eli Eliav --Head of Head of AlgesologyAlgesology Department UMDNJ NJ USADepartment UMDNJ NJ USA

55

Intellectual Property (IP)Intellectual Property (IP)

•• Revolutionary technology.Revolutionary technology.•• Pioneer in minimal invasive procedures in dentistry. Pioneer in minimal invasive procedures in dentistry. •• Patent request (USA) for Patent request (USA) for ““polymeric polymeric stentstent…”…” –– accepted accepted

No.7,195,646 B2 No.7,195,646 B2 .. •• Patent request Patent request ––””pulverizing stones and scar removal in pulverizing stones and scar removal in

soft tissue.soft tissue.””•• U.S. Patent Application No.11/180,917U.S. Patent Application No.11/180,917-- ““A System and A System and

Method for Joint ArthroscopyMethod for Joint Arthroscopy””..•• Patent request Patent request –– ““All in one optical and microscopic All in one optical and microscopic

handlehandle”” August 2007 (PCT).August 2007 (PCT).•• Patent request Patent request –– ““Device and system for Root Canal Device and system for Root Canal

treatment. PCT as A category and to USA (USPTO).treatment. PCT as A category and to USA (USPTO).

66

Salivary Glands Salivary Glands –– the problemthe problem

•• Facial Scars Facial Scars ..•• Damage to facial nerves Damage to facial nerves . . •• Damage to lingual nervesDamage to lingual nerves•• Removal of the salivary gland Removal of the salivary gland -- 30% loss of saliva 30% loss of saliva

functionfunction•• General anesthesia General anesthesia •• Hospitalization 5Hospitalization 5--7 days 7 days •• High costs High costs

77

Salivary Glands Salivary Glands –– The Sialo SolutionThe Sialo Solution

•• No hospitalization No hospitalization •• No external scarring No external scarring •• Success rate 90Success rate 90--95%95%

•• Complete range of products for Complete range of products for the the SialoendoscopySialoendoscopy treatmenttreatment

•• Low costs Low costs •• Minimal risks Minimal risks ..•• Local anesthesia Local anesthesia

Movie S81 (video clip)Movie S81 (video clip)

88

Salivary Glands Salivary Glands –– SummarySummary

The insurance co. in North America can save up to: 300M$ a yearThe insurance co. in North America can save up to: 300M$ a year

No hospitalization costsNo hospitalization costsTotal costs in Israel: Total costs in Israel: $$11,,375375Total costs in USA: Total costs in USA: $$55,,000000

Surgery costs, hospitalization costsSurgery costs, hospitalization costsTotal costs in Israel:Total costs in Israel: $$22,,550550Total costs in USA: Total costs in USA: $$12,00012,000

CostsCosts

••Ambulatory procedureAmbulatory procedure••No facial scarsNo facial scars

••55--7 days of hospitalization7 days of hospitalization••FFacial scarsacial scars

Patient comfortPatient comfort

••Minimal damage to surrounding Minimal damage to surrounding tissue tissue

••No risk to facial an lingual nervesNo risk to facial an lingual nerves

••Severe damage to surroundingSevere damage to surroundingtissuetissue

••Risk to facial and lingual nerves Risk to facial and lingual nerves facial scarsfacial scars

Complications and Complications and other effectsother effects

••A Minimally invasive endoscopic A Minimally invasive endoscopic procedureprocedure

••Under local anesthesiaUnder local anesthesia

••An inpatient procedure An inpatient procedure ••Under general anesthesiaUnder general anesthesia

The procedureThe procedure

SialoSialo--TechnologyTechnologyTechniqueTechnique

SialoSialoadenectomyadenectomyFeatures/techniqueFeatures/technique

99

Salivary Glands Salivary Glands –– Range of productsRange of products

•• CE approved.CE approved.•• FDA approves FDA approves SialoSialo endoscopyendoscopy device.device.•• FDA for FDA for SalivascopeSalivascope expected Q2 / 2009expected Q2 / 2009

1010

Salivary Glands Marketing PlanSalivary Glands Marketing Plan“…“…Conclusions: Conclusions: SialoendoscopySialoendoscopy is a is a

promising new method for use in the promising new method for use in the Diagnosis ,treatmentDiagnosis ,treatment…….Salivary gland .Salivary gland diseases.diseases.”” **

**

1111

Salivary Glands Salivary Glands –– MarketingMarketing

•• Europe: sales on going.Europe: sales on going.

•• USA: orders request from leading USA: orders request from leading medical centersmedical centers: : UCLA, Indiana, UCLA, Indiana, Pittsburgh, Miami ,NYU ,HarvardPittsburgh, Miami ,NYU ,Harvard

•• Expected fast growth of sales in Expected fast growth of sales in USA as result of penetration of USA as result of penetration of the method to central leading the method to central leading medical centers.medical centers.

•• **Not including Japan, Korea, India Not including Japan, Korea, India ––additional market.additional market.

Market potential for disposable,150,000 cases per annum **

0

10,000

20,000

30,000

40,000

50,000

60,000

70,000

6% 10% 25% 50% 70%

% penetration

) K$ (Sales

ב"ארה

USA

EUROPE

recast recast The forecast and/or future events do not constitute a binding foThe forecast and/or future events do not constitute a binding fo

1212

Voice of the leadersVoice of the leaders

•• Mark J. Mark J. RowenRowen-- Former SVP Prudential Equity Group,USA. Senior Wall Street Analyst. Winner of The Wall Street Journal's " BEST on the STREET" award.

“…a force superior technique ,a standard technique for use in USA…”,March 2007.

• Michael D. Turner DDS, MD . NYUCD –“…further these excellent techniques in the United States". June 2005.

• Cleveland Clinic Foundation ** - “…interested in learning you minimally invasive techniques in the treatment of salivary gland disease …”. January2007.2007.

** Cleveland Clinic is ranked one of the top 3 hospitals in America by U.S.News & World Report

1313

Working Channel

Light Fiber

Irrigation Channel

Optical System

Sterilization ProblemsSterilization Problems

Routine cleaning procedures do not remove Routine cleaning procedures do not remove biofilmbiofilmreliably from endoscope channelsreliably from endoscope channels……..**

**Journal of Hospital Infection (2004) 58, 224Journal of Hospital Infection (2004) 58, 224--229229

1414

Our unique solution:Our unique solution:

•• Advantages of this unique system is the full Advantages of this unique system is the full solution for the sterilization problem.solution for the sterilization problem.

•• Financial saving when using Financial saving when using one one ““salivascopesalivascope””+disposables, +disposables, replace 4 endoscopesreplace 4 endoscopes of 0.9of 0.9--2.0 mm. 2.0 mm.

1515

Our unique solution: Our unique solution: Disposable Disposable CannulasCannulas

Sterile traySterile tray

1616

PolyDiagnostPolyDiagnost--Sialo Sialo JointlyJointly ownedowned companycompany shall engage in shall engage in

the marketing andthe marketing and licensing in the USA & licensing in the USA & Canada, as well as inCanada, as well as in obtaining FDA obtaining FDA

approvals and submitting patent approvals and submitting patent applications .applications .

Business Model :Business Model :””Razor & BladesRazor & Blades””

1 Endoscope (reusable) & Disposables 1 Endoscope (reusable) & Disposables

1717

““LaduscopeLaduscope”” -- milk duct endoscopy for breast milk duct endoscopy for breast cancer detectioncancer detection

Assumptions Assumptions •• Disposable products of SialoDisposable products of Sialo--

Poly for Milk duct endoscopy Poly for Milk duct endoscopy estimated 400$/case.estimated 400$/case.

•• Potential market in USA as Potential market in USA as $80 million per annum.$80 million per annum.**

Potential Growth Potential Growth •• Exposure of additional doctors Exposure of additional doctors

(central clinics)(central clinics)•• Cooperation with leading Cooperation with leading

companies in the fieldcompanies in the field

Risks: Risks: new system, slow new system, slow penetration, refunds from penetration, refunds from competitive insurance to competitive insurance to patient.patient.

1 in 8 ,lifetime risk of breast cancer developing (American Cancer Society 2007-2008)

*we estimate on 200,000 cases per annum.

recastrecastThe forecast and/or future events do not constitute a binding foThe forecast and/or future events do not constitute a binding fo

1818

““VitroptikVitroptik”” -- tear channel and ECPtear channel and ECP


Poly for tear channel and ECP Poly for tear channel and ECP 400$/case.400$/case.

•• Potential market in North Potential market in North America as N/A million per America as N/A million per annum.annum.**






•• A A lacrimallacrimal duct obstruction is duct obstruction is blockage of tear duct,blockage of tear duct,

•• ““six to ten percent of all children six to ten percent of all children born before tear ducts are born before tear ducts are open..open..”” **

•• ““often resolve spontaneously, often resolve spontaneously, with 95% showing resolution with 95% showing resolution before the child is one year before the child is one year old..old..””**

* * eMedicine Journal August 2000, eMedicine Journal August 2000, updated on 08updated on 08--1414--20062006

1919

““ArthroptikArthroptik”” –– the small joint endoscopy (TMJ, etc.)the small joint endoscopy (TMJ, etc.)

Assumptions Assumptions •• Disposable products of SialoDisposable products of Sialo--Poly Poly

for (TMJ) for (TMJ) –– Temporo Mandibular Temporo Mandibular Joint endoscopy estimated Joint endoscopy estimated 250$/case.250$/case.

•• Potential market in Europe; North Potential market in Europe; North America and Japan as $75 million America and Japan as $75 million per annum.per annum.**




Risks: Risks: new system, slow penetration, new system, slow penetration, refunds from competitive refunds from competitive insurance to patient.insurance to patient.


2020

Diagnostic Endoscope System for Cancerous Tissues.Diagnostic Endoscope System for Cancerous Tissues.

AssumptionsAssumptions•• Purpose: Early detection with check up Purpose: Early detection with check up

of nonof non--invasive procedure for tobacco invasive procedure for tobacco and alcohol users.and alcohol users.

•• Disposable products of SialoDisposable products of Sialo--Poly Poly N/A $/case.N/A $/case.

•• Potential market in North America Potential market in North America as N/A million per annum.as N/A million per annum.**




Risks: Risks: new system, slow penetration, new system, slow penetration, refunds from competitive refunds from competitive insurance to patient.insurance to patient.


•• The problem The problem -- The diagnosis The diagnosis of suspicious mucosal tissue is of suspicious mucosal tissue is done by biopsy of tissue. done by biopsy of tissue.

•• NYUCD (University of NY) NYUCD (University of NY) advertised in advertised in ““NEXUSNEXUS”” (Fall/Winter (Fall/Winter 2005 vol 7, no. 2) cancer 2005 vol 7, no. 2) cancer operations in the mouth cavity operations in the mouth cavity ––less than 60% patients survived 5 less than 60% patients survived 5 years, only 40% of patients years, only 40% of patients survived 10 years. survived 10 years.

“…“…from a practical perspective, there from a practical perspective, there is the issue of is the issue of ““numbersnumbers””..Approximately 10% of the general Approximately 10% of the general population have oral mucosal population have oral mucosal abnormalitiesabnormalities””**

Oral Surgery, Medicine, Pathology, Radiology and Oral Surgery, Medicine, Pathology, Radiology and Endodontology, Vol. 103 No. 2 February 2007Endodontology, Vol. 103 No. 2 February 2007**

2121

Innovative Technology Innovative Technology and Endoscope for Root and Endoscope for Root

Canal Treatment Canal Treatment

2222

The complete solution is here:The complete solution is here:

As the demand “, added, *HaberJL for innovative dental procedures

Technology has Sialogrows, -positioned itself to meet this ever

increasing demand. We are excited to have them as a guest on our

”program.

Vice President of Programming, *Boca Raton, FL (June 26, 2008) -

Multi-Media Productions (USA), Inc

2323

Root Canal Treatment the unsolvable problem!Root Canal Treatment the unsolvable problem!Treatment still given in the Blind Technique!Treatment still given in the Blind Technique!

•• 17 million teeth are treated for root canal in the 17 million teeth are treated for root canal in the USA.USA.

•• The treatment is given in the blind technique by The treatment is given in the blind technique by dentists dentists –– the chance of success is 65%the chance of success is 65%

•• the endoscope system for the root canal the endoscope system for the root canal treatment treatment –– CE approved. CE approved.

•••• The company complete clinical trials on humans, The company complete clinical trials on humans,

with endoscope for root canal treatment for 15 with endoscope for root canal treatment for 15 cases with authorization of Helsinki Committee cases with authorization of Helsinki Committee successfully (100% success). successfully (100% success).

*According to the American association Of Endodontists an estimated 17 million teeth are saved with root canal procedure each year at the United State only (April,1999).

2424

Root Canal TreatmentRoot Canal Treatment–– SummarySummary

Average rate Average rate -- $1700$1700Average rate - $1500CostsCosts

••Complete controlComplete control••100% vision screening of root 100% vision screening of root procedure + possible intraprocedure + possible intra--operative medication operative medication treatmenttreatment••Possibility of root canal filling Possibility of root canal filling with special design material with special design material under direct visionunder direct vision

•More aggressive treatment•Not all pathologies recognized•Possible un-diagnosed cracks and root fracture •Possible un-diagnosed secondary canals• Possible late infections •Moderate risk procedure

Patient advantage Patient advantage

••Under experimental studyUnder experimental study•65% - Dentist success rate•85% - Endodontist success rate

Complications and Complications and other effectsother effects

* Under direct vision* Under direct vision* Blind Technique* Blind TechniqueThe procedureThe procedure

Sialo Endoscopic Root Canal Sialo Endoscopic Root Canal TreatmentTreatment

Conventional Root CanalConventional Root CanalTreatmentTreatment

Features/techniqueFeatures/technique

2525

Endoscopic Root Canal Treatment Endoscopic Root Canal Treatment –– Dream Dream to Realityto Reality

pal6 (video clip)-Full

2626

The potential extent of income in America The potential extent of income in America alonealone


Poly for root canal treatment Poly for root canal treatment $100/case. $100/case.

•• Potential market in USA as Potential market in USA as $1,700 million per annum. $1,700 million per annum.





*According to the American association Of Endodontists an estimated 17 million teeth are saved with root canal procedure each year at the United State only (April,1999).

recast recast The forecast and/or future events do not constitute a binding foThe forecast and/or future events do not constitute a binding fo

2727

Voice of the leadersVoice of the leaders

• S.Endo, August 2008 - “…this could have great potential as an adjunct to verifying canal cleanliness prior to obturating…”

• Prof’ J.Moshonov , August 2008 - “… endodonticendoscope was used on large series of patients with excellent results…enables diagnosis and most important treatment under direct vision.”

2828

FOR IMMEDIATE RELEASE:Sialo Technology to be featured on

Alexander Haig’s21st Century Health Television

seriesJune 29th, 2008 on CNBC

=oK6QCXwww.youtube.com/watch?vhttp://qMdlM

2929

"VascoCath" "VascoCath" –– steerable catheters for Interventional steerable catheters for Interventional Radiology in the Vascular SystemRadiology in the Vascular System..


Poly for Poly for ””CarotidCarotid”” 1,2001,200 $/case.$/case.•• Potential market in USA as Potential market in USA as

$156 million per annum.$156 million per annum.**






“…“…During the 1990s, about 130,000 During the 1990s, about 130,000 carotid endarterectomies were carotid endarterectomies were performed each year in the United performed each year in the United StatesStates””**

www.surgeryencyclopedia.com/Awww.surgeryencyclopedia.com/A--Ce/CarotidCe/Carotid--Endarterectomy.htmlEndarterectomy.html**

3030

Primary Milestones 2008Primary Milestones 2008--20092009Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4

Salivary Glandsdisposable products - FDA

Marketing in USA + CPT request

Marketing in EUROPE

FDA- (SALIVASCOPE) - Endoscop

Marketing in USA+CPT request (SALIVASCOPE)

Marketing in EUROPE- (SALIVASCOPE)

Marketing in EUROPE, SialoWave - TYPE 2

Endoscopic Root CanalSummary of clinical trials

Request - FDA

Marketing in USA

Diagnostic Endoscope for CancerNon invasive Cancer checkup - NEW TYPE

Other Products disposable - FDA :Laudascope, Vitroptik, Arthroptik..

2008 2009


3131

Sialo Technology Sialo Technology –– Principles.Principles.

•• CE mark for most products. CE mark for most products. •• International reputation with leading medical International reputation with leading medical

centers and universities in Europe and America. centers and universities in Europe and America. •• All our products are All our products are ““Razor & BladesRazor & Blades”” model. model. •• Technological break through via additional uses: Technological break through via additional uses:

endoscopic root canal treatment, nonendoscopic root canal treatment, non--invasive invasive diagnosis of cancer and morediagnosis of cancer and more……

•• Short time to market .Short time to market .

3232

DisclaimerDisclaimer•• All forwardAll forward--looking statements are subject to certain risks, uncertainties alooking statements are subject to certain risks, uncertainties and nd

assumptions. If one or more of these risks or uncertainties mateassumptions. If one or more of these risks or uncertainties materialize, or if rialize, or if underlying assumptions prove incorrect, our actual results, perfunderlying assumptions prove incorrect, our actual results, performance or ormance or achievements could differ materially from those expressed in, orachievements could differ materially from those expressed in, or implied by, implied by, any such forwardany such forward--looking statements. Important factors that could cause or looking statements. Important factors that could cause or contribute to such differences include, among others, changes incontribute to such differences include, among others, changes in general general economic and business conditions, changes in currency exchange reconomic and business conditions, changes in currency exchange rates and ates and interest rates, difficulties or delays in absorbing and integratinterest rates, difficulties or delays in absorbing and integrating acquired ing acquired operations, products, technologies and personnel, changes in busoperations, products, technologies and personnel, changes in business iness strategy and various other factors, as well as those discussed istrategy and various other factors, as well as those discussed in this n this prospectus under prospectus under ‘‘‘‘Risk factors,Risk factors,’’’’..

www.sialotechnology.comwww.sialotechnology.com

Tel: + 972 8 6710795Tel: + 972 8 6710795

Fax: + 972 8 6782524Fax: + 972 8 6782524

[email protected]@sialotechnology.com

11 Ben Gurion Boulevard. (office 220)11 Ben Gurion Boulevard. (office 220)Ashkelon , ISRAELAshkelon , ISRAEL

Sialoendoscopy TMJ Microarthroscopy Breast Endoscopy ... · Salivary Glands –Summary The...

Documents

Transcript of Sialoendoscopy TMJ Microarthroscopy Breast Endoscopy ... · Salivary Glands –Summary The...